Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–5 of 5 results
Advanced filters: Author: "Yves Pommier" Clear advanced filters

  • DNA double strand breaks (DSBs) may lead to cancer but, paradoxically, are also used to kill cancer cells. How might γH2AX — a surrogate marker of DSBs — be used to detect precancerous cells, to stage cancers, to monitor the effectiveness of cancer therapies and to develop novel anticancer drugs?

    • William M. Bonner
    • Christophe E. Redon
    • Yves Pommier
    Reviews
    Nature Reviews Cancer
    Volume: 8, P: 957-967

  • Topoisomerases introduce transient DNA breaks to relax supercoiled DNA, thereby mediating chromatin dynamics and stability, transcription, replication and DNA damage repair. Topoisomerases are targets of various anticancer drugs, and their deregulation can cause, in addition to cancer, neurodegenerative diseases and immune disorders.

    • Yves Pommier
    • Yilun Sun
    • John L. Nitiss
    Reviews
    Nature Reviews Molecular Cell Biology
    Volume: 17, P: 703-721

  • Nuclear DNA topoisomerase I (TOP1) is an essential human enzyme, and is the only known target of the camptothecin and its derivatives. The mechanisms and molecular determinants of the tumour response to TOP1 inhibitors are reviewed in the context of developing camptothecin and non-camptothecin derivatives that further increase anti-tumour activity but also reduce side effects.

    • Yves Pommier
    Reviews
    Nature Reviews Cancer
    Volume: 6, P: 789-802

  • Interfacial inhibitors bind to the interfaces of macromolecular machines (for example, polymerases or ribosomes) and stall their progress. A number of natural product and synthetic interfacial inhibitors are in the clinic for the treatment of cancer and bacterial infections. Here, Pommier and Marchand review the concept of interfacial inhibition, and discuss the rationale and methods for the discovery of novel interfacial inhibitors.

    • Yves Pommier
    • Christophe Marchand
    Reviews
    Nature Reviews Drug Discovery
    Volume: 11, P: 25-36